Summary
Large trial finds nivolumab after lung cancer surgery didn’t improve survival or prevent recurrence compared to observation alone.
Doctors ran a large study to test a drug called nivolumab in people who had surgery to remove lung cancer. This type of cancer is called non-small cell lung cancer, or NSCLC. The question was simple: after surgery and regular treatment like chemotherapy, does giving patients this extra drug help stop the cancer from coming back?
Nivolumab is a type of immunotherapy. That means it helps a person’s own immune system fight cancer cells instead of using chemicals to kill them directly. Doctors already knew this drug helps before surgery. But they didn’t know if it helped after surgery too.
To find out, researchers studied 935 patients across 378 medical centers in the United States. Half of the patients got nivolumab through an IV every four weeks for up to a year. The other half were simply watched closely, without extra treatment. Patients were followed for an average of about six years.
The results were disappointing for the drug. Patients who got nivolumab did not do better than patients who were just watched. Their cancer came back at about the same rate, whether or not they took the drug. Even in a smaller group of patients whose tumors had a marker called PD-L1, which usually means immunotherapy works better, the drug still didn’t show a clear benefit.
Because the drug wasn’t helping, researchers stopped the study early. This is called stopping “for futility,” which means continuing wouldn’t likely change the outcome.
This study is important because it helps doctors understand when immunotherapy drugs like nivolumab actually work and when they don’t. It suggests that giving nivolumab after surgery, on top of standard treatment, may not benefit certain lung cancer patients. This can help doctors avoid using an unnecessary treatment and instead guide patients toward therapies that are more likely to help.
